Related references
Note: Only part of the references are listed.Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
Fei Su et al.
CANCER RESEARCH (2012)
Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure
Koichi Azuma et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Mutant BRAF Melanomas-Dependence and Resistance
Poulikos I. Poulikakos et al.
CANCER CELL (2011)
Combinatorial Treatments That Overcome PDGFRβ-Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition
Hubing Shi et al.
CANCER RESEARCH (2011)
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Nikhil Wagle et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models
Genshi Zhao et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Fyn Is Induced by Ras/PI3K/Akt Signaling and Is Required for Enhanced Invasion/Migration
Vipin Yadav et al.
MOLECULAR CARCINOGENESIS (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Receptor tyrosine kinases and their activation in melanoma
David J. Easty et al.
PIGMENT CELL & MELANOMA RESEARCH (2011)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas
John T. Lee et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression
Kathryn E. Ware et al.
PLoS One (2010)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
Clara Montagut et al.
CANCER RESEARCH (2008)
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells
Elisa Sala et al.
MOLECULAR CANCER RESEARCH (2008)
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Amit Dutt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
James Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Selective Raf inhibition in cancer therapy
Vladimir Khazak et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2007)
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor
Tammie C. Yeh et al.
CLINICAL CANCER RESEARCH (2007)
A module of negative feedback regulators defines growth factor signaling
Ido Amit et al.
NATURE GENETICS (2007)
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
AH Bild et al.
NATURE (2006)
BRAF mutation predicts sensitivity to MEK inhibition
DB Solit et al.
NATURE (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Cell responses to FGFR3 signalling:: growth, differentiation and apoptosis
CGM L'Hôte et al.
EXPERIMENTAL CELL RESEARCH (2005)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer
J Lamb et al.
CELL (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Share Paper
